A generalized health economic and outcomes research model for the evaluation of companion diagnostics and targeted therapies

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 13, Issue 3, 2013, Pages 361-370

  Lee, Jim ^a   Tollefson, Erik ^b   Daly, Matthew ^a   Kielb, Edward ^a  

^a ALTARUM INSTITUTE   (United States)

^b ALTARUM INSTITUTE   (United States)

Author keywords

companion diagnostic testing; cost benefit analysis9; cost effectiveness analysis; targeted cancer therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; COLON CANCER; COLORECTAL CANCER; COMPANION DIAGNOSTIC TEST; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DRUG COST; ECONOMIC EVALUATION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; HEALTH CARE COST; HEALTH ECONOMICS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MATHEMATICAL COMPUTING; MEDICAL PARAMETERS; MEDICAL RESEARCH; NONLINEAR SYSTEM; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; RECTUM CANCER; REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; STATISTICAL PARAMETERS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MODELS, ECONOMIC; MOLECULAR TARGETED THERAPY; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84879388305     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.13.23     Document Type: Review

References (29)

1. Banerjee S, Smith IE. Management of small HER2-positive breast cancers. Lancet Oncol. 11(12), 1193-1199 (2010)
2. Saif MW, Shah M. K-ras mutations in colorectal cancer: a practice changing discovery. Clin. Adv. Hematol. Oncol. 7(1), 45-53, 64 (2009)
3. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am. Fam. Physician 77(3), 311-319 (2008)
4. Pollack A. A push to tie new drugs to testing. New York Times. December (2011)
5. Smith TJ, Hillner BE. Bending the cost curve in cancer care. N. Engl. J. Med. 364(21), 2060-2065 (2011). • An excellent summary of the health economics of cancer care
6. Schulman KA, Tunis SR. A policy approach to the development of molecular diagnostic tests. Nat. Biotechnol. 28(11), 1157-1159 (2010)
7. Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br. J. Cancer 106(6), 1100-1106 (2012). •• Describes key issues for targeting crizotinib therapy in patients with ALK rearrangement, which is currently under consideration for reimbursement in several countries throughout the world
8. Mittmann N, Au HJ, Tu D et al.; Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group; Australasian Gastrointestinal Interest Group. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J. Natl Cancer Inst. 101(17), 1182-1192 (2009)
9. Horgan AM, Bradbury PA, Amir E et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in adVanced non-small-cell lung cancer. Ann. Oncol. 22(8), 1805-1811 (2011)
10. Hedden L, O'Reilly S, Lohrisch C et al. Assessing the real-world cost-effectiveness of adjuVant trastuzumab in HER-2/neu positive breast cancer. Oncologist 17(2), 164-171 (2012)
11. Gaultney JG, Sanhueza E, Janssen JJ, Redekop WK, Uyl-de Groot CA. Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia. Pharmacogenomics 12(3), 411-421 (2011)
12. de Lima Lopes G Jr, Segel JE, Tan DS, Do YK, Mok T, Finkelstein EA. Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with adVanced adenocarcinoma of the lung. Cancer 118(4), 1032-1039 (2012)
13. Lidgren M, Wilking N, Jönsson B, Rehnberg C. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncol. 47(6), 1018-1028 (2008). •• Presents an exceptionally good clinical and economic analysis of a companion diagnostic and its associated therapy
14. Meunnig P. Cost-Effectiveness Analysis in Health-A Practical Approach (2nd Edition). Jossey-Bass, CA, USA (2008). • A good lay-person introduction to cost-effectiveness analysis applied to health
15. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996)
16. Banoo S, Bell D, Bossuyt P. Evaluation of diagnostic tests for infectious diseases: general principles. Nat. Rev. Microbiol. 8(Suppl. 12), S17-S29 (2010)
17. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001)
18. Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuVant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 25(6), 625-633 (2007)
19. Donaldson C, Baker R, Mason H et al. The social value of a QALY: raising the bar or barring the raise? BMC Health Serv. Res. 11, 8 (2011)
20. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br. Med. Bull. 96, 5-21 (2010)
21. Dowsett M, Bartlett J, Ellis IO et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from centres. J. Pathol. 199(4), 418-423 (2003). • The data for Table was drawn from Table 2B, page 420, using immunohistochemistry concordance with FISH to determine sensitivity and specificity of immunohistochemistry
22. Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum. Pathol. 36(3), 250-261 (2005)
23. Press MF, Sauter G, Bernstein L et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin. Cancer Res. 11(18), 6598-6607 (2005)
24. Wolff AC, Hammond ME, Schwartz JN et al.; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor testing in breast cancer. J. Clin. Oncol. 25(1), 118-145 (2007)
25. Barberis M, Pellegrini C, Cannone M, Arizzi C, Coggi G, Bosari S. Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis. Am. J. Clin. Pathol. 129(4), 563-570 (2008)
26. Vijayaragha Van A, Efrusy MB, Göke B, Kirchner T, Santas CC, Goldberg RM. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. Int. J. Cancer 131(2), 438-445 (2012)
27. Engstrom PF, Arnoletti JP, Benson AB 3rd et al.; National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: colon cancer. J. Natl Compr. Canc. Netw. 7(8), 778-831 (2009)
28. Schmiegel W, Reinacher-Schick A, Arnold D et al. Update S3-guideline 'colorectal cancer' 2008. Z. Gastroenterol. 46(8), 799-840 (2008)
29. Schubert C. Cancer drugs find a companion with new diagnostic tests. Nat. Med. 17(10), 1157 (2011)